The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

Archives of Internal Medicine

Volumn 160, Issue 4, 2000, Pages 459-467

  Pearson, Thomas A ^a   Laurora, Irene ^b   Chu, Henry ^b   Kafonek, Stephanie ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0034723758     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.4.459     Document Type: Article

References (24)

1. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987; 317:1237-1245.
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousidian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
3. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, I: reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-364.
4. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med. 1992;152:1490-1500.
5. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
6. National Cholesterol Education Program in Adults. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary. Washington, DC: National Heart, Lung, and Blood Institute, National Institutes of Health; September 1993. NIH publication 93-3096.
7. National Heart, Lung, and Blood Institute. Cholesterol Lowering in the Patient With Coronary Heart Disease: Physician Monograph. Bethesda, Md: National Heart, Lung, and Blood Institute; September 1997. NIH publication 97-3794.
8. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study: implications for clinical practice. Eur Heart J. 1996;17:163-164.
9. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesteroiemia. N Engl J Med. 1995;333:1301-1307.
10. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009.
11. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
12. Downs JR, Clearfield, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
13. Simes RJ, Baker S, MacMahon S, et al. Pravastatin reduces total mortality in patients with coronary heart disease and average cholesterol levels: relationship of baseline cholesterol and treatment effects in the LIPID trials. In: Program and abstracts of the 47th Annual Scientific Session of the American College of Cardiology: March 29-April 1, 1998; Atlanta, Ga. Abstract 1116-4.
14. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S, for the HERS Research Group. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/ Progestin Replacement Study (HERS). JAMA. 1997;277:1281-1286.
15. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
16. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100:605-610.
17. Pearson TA, Kris-Etherton P, Mitchell D, et al. Improving compliance with step I and step II cholesterol-lowering diets: the rural lipid resource center [abstract]. Circulation. 1995:91:936.
18. Allain CC, Poon LS, Chan CBG, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475.
19. McGowan MW, Artiss JD, Strandbergh DR, et al. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29:538-542.
20. 2+ precipitation procedure for the quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982; 28:1379-1388.
21. Friedewald WT, Levy RJ, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Hosmer DW, Hosmer T, Le Cessie, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med. 1997;16:965-980.
23. Arkes HR, Dawson NV, Speroff T, et al, and the SUPPORT Investigators. The covariance decomposition of the probability score and its use in evaluating prognostic estimates. Med Decis Making. 1995;15:120-131.
24. Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM, for the Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Effect of combination therapy drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized placebo controlled trial. Ann Intern Med. 1996;125:529-540.